Covered recipient · General Payments record
LISA NAUJOKS
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2018–2024
$2,444.89
- Reported across 99 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $346.15 | 14 |
| Education | $53.40 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| MILLICENT US INC | $77.75 | 2 |
| SHIELD THERAPEUTICS INC | $68.49 | 1 |
| Exeltis, USA Inc. | $61.75 | 3 |
| Sage Therapeutics, Inc. | $50.96 | 2 |
| ABBVIE INC. | $39.58 | 2 |
| Sumitomo Pharma America, Inc. | $37.41 | 2 |
| Exact Sciences Corporation | $27.04 | 1 |
| CooperSurgical, Inc. | $21.33 | 1 |
| Evofem Biosciences, Inc. | $15.24 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.82 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105104069 | CMS |
| ABBVIE INC. | $16.76 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105104071 | CMS |
| CooperSurgical, Inc. | $21.33 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150796171 | CMS |
| Evofem Biosciences, Inc. | $15.24 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091288493 | CMS |
| Exact Sciences Corporation | $27.04 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114805644 | CMS |
| Exeltis, USA Inc. | $22.89 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150000446 | CMS |
| Exeltis, USA Inc. | $17.88 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150000448 | CMS |
| Exeltis, USA Inc. | $20.98 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150000450 | CMS |
| MILLICENT US INC | $24.35 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150910318 | CMS |
| MILLICENT US INC | $53.40 | 10/07/2024 | Education | Undisputed | 01/23/2026 | 1150910320 | CMS |
| Sage Therapeutics, Inc. | $25.00 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120402844 | CMS |
| Sage Therapeutics, Inc. | $25.96 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120390295 | CMS |
| SHIELD THERAPEUTICS INC | $68.49 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150137877 | CMS |
| Sumitomo Pharma America, Inc. | $21.40 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148895473 | CMS |
| Sumitomo Pharma America, Inc. | $16.01 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148895475 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.